Valuation: 3SBio Inc.

Capitalization 50B 57.35B 7.32B 6.24B 5.77B 5.44B 10.12B 681B 10.33B 67.72B 26.5B 327B 27.48B 26.9B 1,165B P/E ratio 2025
6.33x
P/E ratio 2026 * 18.2x
Enterprise value 40.2B 46.11B 5.89B 5.02B 4.64B 4.37B 8.14B 548B 8.31B 54.46B 21.31B 263B 22.1B 21.63B 937B EV / Sales 2025
2.32x
EV / Sales 2026 * 3.66x
Free-Float
72.15%
Yield 2025
1.01%
Yield 2026 * 1.23%
1 day+0.70%
1 week-9.54%
Current month+1.41%
1 month+5.03%
3 months-16.99%
6 months-18.29%
Current year-5.05%
1 week 22.38
Extreme 22.38
25.96
1 month 20.42
Extreme 20.42
26.2
Current year 19.27
Extreme 19.27
29.3
1 year 10.94
Extreme 10.94
36.8
3 years 4.91
Extreme 4.91
36.8
5 years 4.72
Extreme 4.72
36.8
10 years 4.72
Extreme 4.72
36.8
Manager TitleAgeSince
Chief Executive Officer 63 01/01/2006
Director of Finance/CFO - 03/07/2023
Corporate Officer/Principal 56 27/11/2014
Director TitleAgeSince
Chairman 63 03/04/2012
Director/Board Member 56 11/06/2012
Director/Board Member 57 01/06/2015
Change 5d. change 1-year change 3-years change Capi.($)
+0.70%-9.54%+94.91%+188.44% 7.32B
-2.47%-1.70%+37.06%-9.09% 76.85B
+1.18%+3.97%+104.23%+219.62% 61.45B
-0.57%+57.10%+57.10%+57.10% 49.05B
-0.74%+0.19%-42.43%-53.63% 47.32B
-2.34%-2.46%+52.56%-38.85% 25.38B
-0.62%+3.58%+108.00%-68.18% 20.21B
+0.85%-3.28%+102.52%+130.77% 19.61B
-0.92%+0.15%+74.13%+29.95% 19.12B
+1.04%+1.35%+62.09%+61.96% 15.18B
Average -0.39%-0.33%+65.02%+51.81% 34.15B
Weighted average by Cap. -0.68%+0.82%+54.55%+47.30%

Financials

2025 2026 *
Net sales 18.44B 21.16B 2.7B 2.3B 2.13B 2.01B 3.73B 251B 3.81B 24.98B 9.78B 121B 10.14B 9.92B 430B 10.62B 12.18B 1.56B 1.33B 1.23B 1.15B 2.15B 145B 2.2B 14.39B 5.63B 69.48B 5.84B 5.71B 248B
Net income 9.59B 11B 1.4B 1.2B 1.11B 1.04B 1.94B 131B 1.98B 12.99B 5.08B 62.71B 5.27B 5.16B 223B 2.8B 3.21B 410M 349M 323M 304M 567M 38.14B 579M 3.79B 1.48B 18.31B 1.54B 1.51B 65.25B
Net Debt -9.79B -11.23B -1.43B -1.22B -1.13B -1.06B -1.98B -133B -2.02B -13.27B -5.19B -64.06B -5.38B -5.27B -228B -11.12B -12.75B -1.63B -1.39B -1.28B -1.21B -2.25B -151B -2.3B -15.06B -5.89B -72.71B -6.11B -5.98B -259B
Logo 3SBio Inc.
3SBio Inc is an investment holding company mainly engaged in the development, production, marketing and sale of pharmaceutical products. The Company’s core products include several biopharmaceutical drugs, TPIAO, recombinant human erythropoietin(rhEPO) products, with brand of EPIAO and SEPO, Yisaipu, Cipterbin and a small molecule drug, Mandi and tumor necrosis factor (TNF). Through its subsidiaries, the Company is engaged in project management and consultation. The Company still engages in developing innovative biological products, including mAbs, bi-specific antibodies and fusion proteins, and a number of small molecule drugs, both innovative and generic, in the areas of nephrology, oncology, auto-immune and inflammatory diseases, ophthalmology and dermatological diseases. The Company distributes its products within the domestic market and to overseas markets.
Employees
6,109
Date Price Change Volume
10/04/26 22.96 $ +0.70% 30,015,150
09/04/26 22.80 $ -4.04% 39,970,370
08/04/26 23.76 $ -6.38% 63,073,740
02/04/26 25.38 $ +0.24% 57,347,110
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
20.02CNY
Average target price
33.08CNY
Spread / Average Target
+65.26%

Quarterly revenue - Rate of surprise